Streetbeat News

Price Targets

STKS

Wedbush analyst Nick Setyan reiterates a Neutral rating on The One Group Hospitality (STKS) and maintains a $5 price target.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 3:28 pm

AR

JP Morgan analyst Arun Jayaram has maintained an Overweight rating on Antero Resources (NYSE:AR) and increased the price target from $30 to $32.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 3:26 pm

KDP

Jefferies analyst Kaumil Gajrawala maintains a Buy rating on Keurig Dr Pepper (NASDAQ:KDP) but lowers the price target from $37 to $35.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 3:16 pm

DASH

JMP Securities analyst Andrew Boone has maintained a Market Outperform rating on DoorDash (NASDAQ:DASH) and increased the price target from $130 to $160.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 3:07 pm

FDX

Analysts have diverse opinions on FedEx (NYSE:FDX), with recent evaluations showing a mix of ratings from bullish to bearish. The average 12-month price target for FDX is $295.06, marking a 5.68% increase from the previous target. Analyst actions include rating changes and price target adjustments, reflecting their views on FedEx's market performance and financial health. FedEx's financial indicators suggest a strong market position, despite a -1.94% decline in revenue growth over the last 3 months.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 3:01 pm

BEAM

In the last three months, 4 analysts have updated their ratings on Beam Therapeutics (NASDAQ:BEAM), showing a shift towards a more positive outlook with an average 12-month price target of $43.5, reflecting a 43.42% increase from the previous average of $30.33. The company has shown significant financial growth, with a revenue increase of 1478.04% as of December 31, 2023, and outperforms industry averages in net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 3:01 pm

BGNE

Four analysts have recently updated their ratings on BeiGene (NASDAQ:BGNE), showing a mix of bullish to indifferent sentiments. The average 12-month price target is now $219.25, down from $243.33, with ratings adjustments reflecting changes in market conditions and company performance. BeiGene, a biotech firm focused on cancer treatment drugs, has shown a significant revenue growth rate of 66.91% as of December 31, 2023, but struggles with profitability and efficiency metrics like net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 3:00 pm

BK

Bank of New York Mellon (NYSE:BK) has seen varied analyst ratings over the last three months, with a shift towards a more neutral stance in the last 30 days. The average 12-month price target has been raised to $61.75, indicating a bullish outlook from analysts. Key analysts from RBC Capital, Citigroup, Morgan Stanley, and UBS have updated their ratings and price targets, reflecting changes in market conditions and company performance. Despite this, BNY Mellon faces challenges in revenue growth, net margin, ROE, and ROA, compared to industry averages.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 3:00 pm

RGLD

Royal Gold's stock is trading higher following an upgrade by BMO Capital from Market Perform to Outperform, with a raised price target from $148 to $158.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 2:59 pm

ARGX

HC Wainwright & Co. analyst Douglas Tsao maintains a Buy rating on argenx (NASDAQ:ARGX) with a maintained price target of $451.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 2:49 pm